CHRONOLOGY: Drug company Biovail's legal woes
TORONTO (Reuters) - The U.S. Securities and Exchange Commission charged Biovail Corp (BVF.TO) (BVF.N), two current senior executives and founder and former Chief Executive Eugene Melnyk on Monday with engaging in a number of fraudulent accounting schemes.
Following is a list of key dates of the drug company's legal issues:
March 24, 2008 - SEC charges Biovail and senior executives with accounting fraud. Company agrees to pay $10 million penalty to settle the charges.
March 24, 2008 - Ontario Securities Commission sets April 22 hearing date for Biovail insiders.
February 1, 2008 - Biovail faces U.S. grand jury probe over marketing of Cardizem heart drug.
December 11, 2007 - Biovail settles U.S. shareholder lawsuit that stretched back more than four years.
September 11, 2007 - Biovail settles with Banc of America Securities analyst.
May 18, 2007 - Ontario Securities Commission approves deal that settles trading disclosure allegations against company founder Eugene Melnyk.
February 22, 2006 - Biovail files lawsuit alleging stock market manipulation scheme.
November 20, 2003 - Biovail confirms informal inquiry by SEC into accounting and financial reporting practices.
August 22, 2003 - Biovail initially receives administrative inquiry from U.S. Office of the Inspector General into marketing programs related to Cardizem.
($1=$1.02 Canadian)
(Reporting by Scott Anderson; editing by Rob Wilson)
